APA (7th ed.) Citation

Wainwright, C., McColley, S., McNally, P., Powers, M., Ratjen, F., Rayment, J., . . . Davies, J. (2024). 148 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: Final results from a 192-week extension study. Journal of Cystic Fibrosis, 23, S82. https://doi.org/10.1016/S1569-1993(24)00989-5

Chicago Style (17th ed.) Citation

Wainwright, C., et al. "148 Long-term Safety and Efficacy of Elexacaftor/tezacaftor/ivacaftor in Children Aged 6 and Older with Cystic Fibrosis and at Least One F508del Allele: Final Results from a 192-week Extension Study." Journal of Cystic Fibrosis 23 (2024): S82. https://doi.org/10.1016/S1569-1993(24)00989-5.

MLA (9th ed.) Citation

Wainwright, C., et al. "148 Long-term Safety and Efficacy of Elexacaftor/tezacaftor/ivacaftor in Children Aged 6 and Older with Cystic Fibrosis and at Least One F508del Allele: Final Results from a 192-week Extension Study." Journal of Cystic Fibrosis, vol. 23, 2024, p. S82, https://doi.org/10.1016/S1569-1993(24)00989-5.